Skip to content
FDAMedicines

Baxter Issues Voluntary Nationwide Recall for One Lot of Anticoagulant Sodium Citrate Solution Due to Potential Presence of Particulate Matter

FDA recall n-baxter-issues-voluntary-nationwide-recall-one-lot-anticoagulant-sodium-citrate-s ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Potential presence of particulate matter identified as fiberglass in the solution
Text from FDA, unedited.

The recalled product

FOR IMMEDIATE RELEASE – AUG. 25, 2026 – DEERFIELD, Ill., Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of Anticoagulant Sodium Citrate Solution due to the potential presence of particulate matter identified as fiberglass in the solution.
Text from FDA, unedited.

Company announcement, as FDA publishes it

FOR IMMEDIATE RELEASE – AUG. 25, 2026 – DEERFIELD, Ill. , Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of Anticoagulant Sodium Citrate Solution due to the potential presence of particulate matter identified as fiberglass in the solution.

Risk Statement : Anticoagulant Sodium Citrate Solution is intended for use with automated apheresis devices. Administration of Anticoagulant Sodium Citrate containing particulate matter may lead to adverse health consequences, the extent and severity of harm depend on the size, number, morphology and composition of the foreign material. In the absence of in-line filtration, these particles may cause local vein irritation, inflammatory or hypersensitivity reactions, and systemic embolization that could result in tissue or organ injury. As of 8/25/2026, Baxter has not received any reports of adverse events related to this issue.

The product is intended for use only with apheresis devices. It is not for direct intravenous infusion and the directions for use are contained in the owners operating and maintenance manual of the apheresis machine to be used. The product is packaged in 250 mL VIAFLEX Plastic Containers, with 36 units per case. Additional information can be found in the table below.

Affected Product :

The affected lot can be identified by locating the lot number and expiration date on the individual product and shipping carton, as shown in the images below.

The impacted product was distributed from 7/2/2026 to 7/11/2026 to one customer in the United States.

The customer should immediately discontinue use of and return all affected units in accordance with their facility’s process. Baxter is contacting the customer by email with instructions on how to identify and return the impacted product.

For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online : www.fda.gov/medwatch/report.htm

Regular Mail or Fax : Download form www.fda.gov/MedWatch/getforms.htm 2 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

The United States Food and Drug Administration (FDA) has been notified of this action.

Text from FDA (the company’s words), unedited.
  • 2B7867Q Anticoagulant Sodium Citrate Solution USP, 250 mL VIAFLEX Plastic Container

    Lot or code
    Lot Number: Y493475; Expiration Date: 31-Dec-2027; NDC Number: 0338-9669-01

Source

Issued by
U.S. Food and Drug Administration
Firm
Baxter International Inc.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: Baxter International Inc., Month: August 2026, Week 2026-W35. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Potential presence of particulate matter identified as fiberglass in the solution”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on August 25, 2026.

Other notices of Baxter International Inc.